Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto.
Schedule
| Product: | Halaven |
| Active Ingredient: | Eribulin mesilate 0.5mg/mL equivalent to eribulin 0.44mg/mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | Eisai New Zealand Limited |
| Manufacturers: | NerPharMa SRL, Nerviano, Italy BSP Pharmaceuticals SpA, Latina, Italy |
Dated this 19th day of April 2024.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).